Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients

Perry B. Hooper; Aaron S. Farberg; Alison L. Fitzgerald; Jennifer J. Siegel; Briana B. Rackley; Anesh Prasai; Sarah J. Kurley; Matthew S. Goldberg; Graham H. Litchman

doi:10.1080/07357907.2022.2116454

Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients

Perry B. Hooper, Aaron S. Farberg, Alison L. Fitzgerald, Jennifer J. Siegel, Briana B. Rackley, Anesh Prasai, Sarah J. Kurley, Matthew S. Goldberg, Graham H. Litchman

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Treatment decisions for patients with cutaneous squamous cell carcinoma (cSCC) are traditionally based upon clinicopathologic risk factors and staging systems. Due to the accuracy limitations of these resources in predicting poor outcomes, there is a clinically significant need for more accurate methods of risk assessment. The 40-gene expression profile (40-GEP) test was developed to augment metastatic risk prediction of high-risk cSCC patients and has been validated in two independent, multi-center studies involving over 1,000 patients. This study substantiates that the 40-GEP is appropriately utilized by clinicians and that the personalized risk-stratification results are impactful in guiding risk-aligned patient management.

Original language	English
Pages (from-to)	911-922
Number of pages	12
Journal	Cancer Investigation
Volume	40
Issue number	10
DOIs	https://doi.org/10.1080/07357907.2022.2116454
State	Published - 2022
Externally published	Yes

Keywords

40-gene expression profile (40-GEP)
Cutaneous squamous cell carcinoma (cSCC)
metastasis
prognostic
risk-stratification

Access to Document

10.1080/07357907.2022.2116454

Cite this

Hooper, P. B., Farberg, A. S., Fitzgerald, A. L., Siegel, J. J., Rackley, B. B., Prasai, A., Kurley, S. J., Goldberg, M. S., & Litchman, G. H. (2022). Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients. Cancer Investigation, 40(10), 911-922. https://doi.org/10.1080/07357907.2022.2116454

@article{3080f495c0444a1fa7e2d4fb90a4885f,

title = "Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients",

abstract = "Treatment decisions for patients with cutaneous squamous cell carcinoma (cSCC) are traditionally based upon clinicopathologic risk factors and staging systems. Due to the accuracy limitations of these resources in predicting poor outcomes, there is a clinically significant need for more accurate methods of risk assessment. The 40-gene expression profile (40-GEP) test was developed to augment metastatic risk prediction of high-risk cSCC patients and has been validated in two independent, multi-center studies involving over 1,000 patients. This study substantiates that the 40-GEP is appropriately utilized by clinicians and that the personalized risk-stratification results are impactful in guiding risk-aligned patient management.",

keywords = "40-gene expression profile (40-GEP), Cutaneous squamous cell carcinoma (cSCC), metastasis, prognostic, risk-stratification",

author = "Hooper, {Perry B.} and Farberg, {Aaron S.} and Fitzgerald, {Alison L.} and Siegel, {Jennifer J.} and Rackley, {Briana B.} and Anesh Prasai and Kurley, {Sarah J.} and Goldberg, {Matthew S.} and Litchman, {Graham H.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2022",

doi = "10.1080/07357907.2022.2116454",

language = "English",

volume = "40",

pages = "911--922",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "10",

}

Hooper, PB, Farberg, AS, Fitzgerald, AL, Siegel, JJ, Rackley, BB, Prasai, A, Kurley, SJ, Goldberg, MS & Litchman, GH 2022, 'Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients', Cancer Investigation, vol. 40, no. 10, pp. 911-922. https://doi.org/10.1080/07357907.2022.2116454

Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients. / Hooper, Perry B.; Farberg, Aaron S.; Fitzgerald, Alison L. et al.
In: Cancer Investigation, Vol. 40, No. 10, 2022, p. 911-922.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients

AU - Hooper, Perry B.

AU - Farberg, Aaron S.

AU - Fitzgerald, Alison L.

AU - Siegel, Jennifer J.

AU - Rackley, Briana B.

AU - Prasai, Anesh

AU - Kurley, Sarah J.

AU - Goldberg, Matthew S.

AU - Litchman, Graham H.

PY - 2022

Y1 - 2022

N2 - Treatment decisions for patients with cutaneous squamous cell carcinoma (cSCC) are traditionally based upon clinicopathologic risk factors and staging systems. Due to the accuracy limitations of these resources in predicting poor outcomes, there is a clinically significant need for more accurate methods of risk assessment. The 40-gene expression profile (40-GEP) test was developed to augment metastatic risk prediction of high-risk cSCC patients and has been validated in two independent, multi-center studies involving over 1,000 patients. This study substantiates that the 40-GEP is appropriately utilized by clinicians and that the personalized risk-stratification results are impactful in guiding risk-aligned patient management.

AB - Treatment decisions for patients with cutaneous squamous cell carcinoma (cSCC) are traditionally based upon clinicopathologic risk factors and staging systems. Due to the accuracy limitations of these resources in predicting poor outcomes, there is a clinically significant need for more accurate methods of risk assessment. The 40-gene expression profile (40-GEP) test was developed to augment metastatic risk prediction of high-risk cSCC patients and has been validated in two independent, multi-center studies involving over 1,000 patients. This study substantiates that the 40-GEP is appropriately utilized by clinicians and that the personalized risk-stratification results are impactful in guiding risk-aligned patient management.

KW - 40-gene expression profile (40-GEP)

KW - Cutaneous squamous cell carcinoma (cSCC)

KW - metastasis

KW - prognostic

KW - risk-stratification

UR - http://www.scopus.com/inward/record.url?scp=85138186028&partnerID=8YFLogxK

U2 - 10.1080/07357907.2022.2116454

DO - 10.1080/07357907.2022.2116454

M3 - Article

C2 - 36073945

AN - SCOPUS:85138186028

SN - 0735-7907

VL - 40

SP - 911

EP - 922

JO - Cancer Investigation

JF - Cancer Investigation

IS - 10

ER -

Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this